Quick Answer
eCTD Module 1 contains regional administrative and prescribing information. It is the only CTD module that is not harmonized globally. In FDA submissions, Module 1 includes forms, cover letters, administrative information, labeling, REMS, promotional material where applicable, and other region-specific content controlled through the regional Module 1 backbone.
Key Takeaways
- Module 1 is region-specific; Modules 2-5 follow the harmonized ICH CTD structure.
- FDA Module 1 structure is defined by FDA regional Module 1 specifications, not only by ICH M4.
- Module 1 is where application forms, cover letters, administrative information, and labeling usually sit.
- In eCTD v3.2.2, Module 1 is represented through the regional backbone file, while Modules 2-5 use the ICH backbone.
- Most Module 1 problems are administrative: wrong form, outdated labeling, missing cover letter context, or incorrect regional placement.
- This article focuses on eCTD Module 1 structure. For a broader regional requirements article, see the eCTD Module 1 guide. For the full five-module framework, see eCTD structure explained.
Why Module 1 Deserves Extra Attention
Module 1 may look administrative, but it can affect whether the submission is received, routed, understood, and reviewed efficiently. A technically strong Module 3, 4, or 5 package can still run into avoidable problems if Module 1 uses outdated forms, unclear cover letter language, inconsistent application identifiers, or labeling that does not match the rest of the submission.
For FDA submissions, Module 1 helps answer practical questions before review begins:
- What application or sequence is this?
- What is the submission type and purpose?
- Which forms are included?
- What labeling is being submitted or changed?
- What administrative commitments, requests, or designations apply?
- Which correspondence, meeting, REMS, pediatric, or promotional materials are relevant?
- How should FDA route and interpret this sequence?
That context should be precise. Module 1 is not the place for generic filing language copied from a prior application without review.
What Is eCTD Module 1?
eCTD Module 1 is the regional administrative module of a regulatory submission. It contains information that each health authority requires for legal, administrative, labeling, and application processing purposes.
ICH M4 identifies Module 1 as administrative information and prescribing information. Unlike Modules 2, 3, 4, and 5, Module 1 is not intended to be common across all regions.
That distinction matters. A sponsor may reuse much of Modules 2-5 across FDA, EMA, Health Canada, and other authorities, but Module 1 usually needs to be rebuilt for each region.
FDA eCTD Module 1 Structure
FDA Module 1 is more detailed than the high-level ICH Module 1 description. The exact heading hierarchy depends on FDA's current regional Module 1 specifications and comprehensive table of contents.
| FDA Module 1 Area | Typical Content |
|---|---|
| 1.1 Forms | Application forms and required FDA forms |
| 1.2 Cover letters | Submission cover letter and administrative context |
| 1.3 Administrative information | Patent, exclusivity, financial disclosure, user fee, and related information |
| 1.4 References | Letters of authorization and cross-references |
| 1.5 Application status | Information related to application status where applicable |
| 1.6 Meetings | Meeting requests, briefing packages, and correspondence where applicable |
| 1.7 Fast Track | Fast Track designation material where applicable |
| 1.8 Special Protocol Assessment | SPA request and related correspondence where applicable |
| 1.9 Pediatric information | Pediatric plans, waivers, deferrals, or related information |
| 1.10 Dispute resolution | Formal dispute resolution material |
| 1.11 Information amendment | Information amendments and related content |
| 1.12 Other correspondence | Other FDA correspondence |
| 1.13 Annual reports | Annual report content for applicable application types |
| 1.14 Labeling | Prescribing information, carton/container labeling, patient labeling, and related files |
| 1.15 REMS | Risk Evaluation and Mitigation Strategy content where applicable |
| 1.16 Promotional material | Promotional material submissions where applicable |
| 1.17 Risk assessment | Environmental assessment or categorical exclusion information |
Not every section applies to every application. The correct Module 1 structure depends on the application type, submission type, product, regulatory history, and FDA instructions.
What Belongs in Module 1 and What Does Not
Module 1 should contain regional administrative and prescribing information. It should not become a catch-all folder for scientific reports that belong in Modules 2-5.
| Content Type | Typical Placement Logic |
|---|---|
| FDA forms | Module 1, under the relevant forms heading |
| Cover letter | Module 1, usually early in the regional structure |
| Proposed labeling | Module 1 labeling sections |
| Patent, exclusivity, user fee, or financial disclosure information | Module 1 administrative sections |
| REMS content | Module 1 REMS sections where applicable |
| Quality study report | Usually Module 3, not Module 1 |
| Nonclinical study report | Usually Module 4, not Module 1 |
| Clinical study report | Usually Module 5, not Module 1 |
| Summary of quality, nonclinical, or clinical evidence | Usually Module 2 |
If a document seems administrative and scientific at the same time, decide based on the regulatory question it answers. For example, the label itself belongs in Module 1, while the clinical evidence supporting a label claim belongs in Module 5 and is summarized in Module 2.
Module 1 Is Regional, Not Universal
The core mistake with Module 1 is assuming it behaves like the rest of the CTD. It does not.
| Region | Module 1 Implication |
|---|---|
| FDA | Uses FDA regional Module 1 specifications and FDA forms |
| EMA | Uses EU administrative forms, product information, and regional requirements |
| Health Canada | Uses Canadian administrative and regional requirements |
| PMDA | Uses Japan-specific administrative structure |
The technical and scientific modules may be similar across regions, but Module 1 is where each agency's local filing rules appear.
eCTD Technical Structure for Module 1
In eCTD v3.2.2, Module 1 is controlled separately from Modules 2-5. The regional backbone file provides Module 1 navigation and metadata for the regional content.
Practical structure points:
- Module 1 content should be placed under the correct regional headings.
- The regional backbone should use currently supported FDA Module 1 specifications.
- Leaf titles should be clear and match the document purpose.
- Forms and labeling should be current for the submission date.
- Cover letter language should match the application type and sequence purpose.
- Module 1 content should cross-reference Modules 2-5 only where needed and accurately.
FDA supports eCTD v3.2.2 and eCTD v4.0 for CDER and CBER submissions. Teams should use the version currently supported in FDA's Data Standards Catalog and the applicable submission standards.
Cover Letter and Sequence Purpose
The cover letter should help FDA understand the purpose of the sequence. It should not be treated as a formality.
A useful cover letter usually makes clear:
- Application number or pre-assigned number, where applicable
- Submission type and sequence purpose
- Product name and applicant information
- Whether the sequence is original, amendment, supplement, response, annual report, promotional submission, meeting package, or another type
- Key documents included in the sequence
- Relevant cross-references or prior communications
- Contact information
- Any important timing or review context
The cover letter should match the eCTD metadata and the actual contents of the sequence. If the cover letter says the sequence is a response but the backbone metadata or folder contents imply a different purpose, administrative review can become harder.
Labeling in Module 1
Labeling is one of the highest-risk Module 1 areas because it must align with the rest of the application. Proposed prescribing information, container/carton labeling, patient labeling, medication guides, instructions for use, and related materials should be current and placed under the correct regional headings.
Before submission, check that labeling aligns with:
- Proposed indication and dosage
- Clinical efficacy and safety conclusions
- Warnings, contraindications, and adverse event evidence
- CMC details that affect storage, handling, presentation, or administration
- REMS or medication guide content where applicable
- Prior labeling negotiations or commitments
Labeling mismatches are not just formatting issues. They can create substantive review questions when Module 1 claims do not match the evidence in Modules 2-5.
Common Module 1 Structure Errors
| Error | Why It Matters |
|---|---|
| Wrong heading placement | Reviewers may not find the administrative document where expected |
| Outdated FDA form | Administrative review can be delayed |
| Missing cover letter detail | FDA may lack context for the sequence purpose |
| Labeling in the wrong location | Labeling review and validation can be affected |
| Inconsistent application number or sequence purpose | Receipt and lifecycle tracking can be disrupted |
| Regional content copied across markets without adaptation | Local authority requirements may be missed |
Module 1 is often where otherwise strong submissions fail basic administrative readiness.
Module 1 Readiness Checklist
Before filing, review:
- Current FDA forms are used.
- Application number, sequence number, and submission type are consistent.
- Cover letter matches the sequence content.
- Labeling files are current, complete, and correctly placed.
- Administrative documents are under correct regional headings.
- Cross-references and letters of authorization are valid.
- REMS, pediatric, promotional, or environmental sections are included only where applicable.
- Regional XML and leaf titles are clear and compliant with current supported standards.
- No scientific reports are misplaced into Module 1 because the team was unsure where to put them.
This checklist catches many avoidable administrative issues before submission.
How Assyro Supports Module 1 Readiness
Assyro helps regulatory teams validate whether Module 1 content is complete, current, and consistent with the submission purpose. eCTD Validation, eCTD Authoring, and Regulatory Gap Analysis can help identify missing forms, inconsistent metadata, weak cover letter context, and labeling placement issues before submission.
For Module 1, the value is administrative precision: the right document, in the right place, for the right region and sequence.
eCTD Module 1 contains regional administrative and prescribing information, including forms, cover letters, labeling, and other region-specific documents.
References
This guide reflects FDA and ICH eCTD structure information current as of May 2026. Confirm current regional Module 1 specifications and FDA submission standards before filing.
About the author
Assyro Team
Expert regulatory operations consultants helping pharmaceutical companies navigate complex compliance challenges.
See Assyro in action
Catch eCTD and eSTAR errors before your FDA review cycle.
Book a 20-minute demo this week. We'll validate a sample of your submission live and show you exactly where Assyro catches what your current QC misses.